CDC73
CDC73 (Parafibromin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Endometrial cancer, Colorectal cancer and 1 more.
Overview
Tumour suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency.
Open Targets scores its association with cancer at 0.85 (direct and indirect evidence; datatypes genetic literature 0.86, literature 0.93, genetic association 0.76, somatic mutation 0.89, animal model 0.50). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Endometrial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CDC73 (Parafibromin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Endometrial cancer, Colorectal cancer and 1 more.
- 1 · What it is
CDC73 (Parafibromin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Endometrial cancer, Colorectal cancer and 1 more.
- 2 · What goes wrong in cancer
Tumour suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression.
- 3 · How drugs use it
No product in this corpus aims at CDC73 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:16783 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6P1J9 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000134371 (association with cancer (MONDO_0004992) 0.85; per-cancer scores at or above 0.5: colorectal cancer 0.52, breast cancer 0.65, lung cancer 0.51 (GraphQL API, CC0)); IntOGen CDC73 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Tumour suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in haematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. Location: Nucleus (UniProt). Locus 1q31.2 (HGNC).
- Breast cancer: Open Targets association 0.65 with breast cancer (MONDO_0007254)
- Endometrial cancer: IntOGen driver in 1 cohort (UCEC)
- Colorectal cancer: Open Targets association 0.52 with colorectal cancer (MONDO_0005575)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CDC73" OR ABSTRACT:"CDC73" OR TITLE:"cell division cycle 73" OR ABSTRACT:"cell division cycle 73" OR TITLE:"Parafibromin" OR ABSTRACT:"Parafibromin" OR TITLE:"parafibromin" OR ABSTRACT:"parafibromin" OR TITLE:"C1orf28" OR ABSTRACT:"C1orf28" OR TITLE:"HRPT2" OR ABSTRACT:"HRPT2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDC73, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTRIM33
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetRSPO3
Shares Lung cancer (all types), Breast cancer (all types), Open Targets Platform, Colorectal cancer.
- TargetAFDN
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetATP2B3
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetEIF3E
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetABL2
Shares Lung cancer (all types), Endometrial cancer, Breast cancer (all types), IntOGen.
- TargetNDRG1
Shares Lung cancer (all types), Breast cancer (all types), Open Targets Platform, Colorectal cancer.
- TargetAFF4
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.